AGP Executive Report
Last update: 5 hours agoMedical Devices & Trade: Qatar’s QMED 2026 (Oct. 14–16) adds Apex Health as a strategic sponsor, spotlighting regional healthcare capacity-building and medical tech partnerships. Oncology Research: At ProsTIC 2026, investigators shared early moves to bring PSMA radioligand therapy forward in prostate cancer, including a phase 1 neoadjuvant 177Lu-PSMA-I&T plus moderately hypofractionated radiotherapy plan for high-risk localized disease. AI in Cancer Care: ProsTIC also highlighted “PETomics” that blends PET imaging with ctDNA using deep learning to predict response to 177Lu-PSMA-617 in mCRPC, alongside open-source AI for PSMA PET/CT segmentation and prognostic biomarker extraction. Cardiovascular Drug Setback: Novartis and Ionis’ pelacarsen (Lp(a) lowering) missed the primary endpoint in the Lp(a)HORIZON phase 3 trial, failing to reduce major cardiovascular events despite lowering Lp(a). Mental Health & Community Care: Canada marks World Suicide Prevention Day (Sept. 10) with a push to change the narrative and strengthen culturally safer, regional prevention supports. Public Health Action: Mississippi expands naloxone vending machines at hospitals to curb overdoses, with fentanyl still a key concern.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
